Brendan Fish will oversee the expansion of the company’s RNA capabilities at its National Biologics Manufacturing Centre
CPI has announced Brendan Fish - currently Director of New Product Introduction, Process Technology at GSK - will join CPI in May 2022, where he will work as Director of Biologics. In this role, Dr Fish will bring together academia, industry, government to scale-up and commercialise biologics technologies.
He will also lead the company’s work on RNA technology, targeting conditions including flu, HIV, Zika and cancer. He will oversee the expansion of the company’s RNA capabilities at its National Biologics Manufacturing Centre, including GMP facilities for the clinical manufacture of RNA and a training academy for RNA therapeutics and vaccines.
Dr Fish said: “I am very excited to be joining CPI at this crucial time in its growth of biologics and RNA vaccines. The work CPI does to support the development of medicines is incredible and inspiring, and I am looking forward to leveraging my experience to support CPI’s talented people and cutting-edge projects.”
Dave Tudor, Director of Medicines Manufacturing, Biologics and Quality at CPI, said: “I am delighted to welcome Brendan as the new Director for Biologics. This is a growing and fast-paced area within the pharma sector and CPI are well-placed to provide significant value to patients and industry through advanced technology solutions. Brendan’s experience and leadership will play a significant role in CPI’s growth plans in this area.”